Aligos Therapeutics Inc ALGS.NASDAQ Chart and Quote
|
ALGS Today's High:
|
$9.1
|
ALGS Shares One Week Perf:
|
18.47 %
|
| ALGS Today's Low: |
$ 8.18 |
ALGS Shares 30 Day Performance: |
43.14 % |
| Number of ALGS Shares Traded (M): |
289 |
ALGS Share Price 52 Wk High: |
$ 46.80 |
| Value of ALGS's Shares Traded (M$): |
$ 2,504 |
ALGS Share Price 52 Wk Avg: |
$14.70 |
| Share Price at the Open: |
$8.38 |
ALGS's Share Price 52 Wk Low: |
$3.76 |
Over the course of the last five trading days Aligos Therapeutics Inc stock dropped by % , this brings the year to date performance to -78.25%. Aligos Therapeutics Inc stock is currently trading on the NASDAQ by -41.2% below its 52 week average.
Aligos Therapeutics Inc 's share price is delayed for 15 minutes
Select the Period on the chart to see the ALGS.NASDAQ's share price performance, or type custom period of your choice
ALGS Company Profile >> Share performance within Biotechnology & Pharmaceuticals Industry >> Compare ALGS to its Benchmarks |
News about Aligos Therapeutics Inc's Stock Splits and Dividends |
|
March 14, 2025
Aligos Therapeutics Moves Forward with Strategic Inducement Grants to Attract TalentSOUTH SAN FRANCISCO, Calif. Aligos Therapeutics, Inc. (Nasdaq: ALGS), a promising player in the clinical-stage biopharmaceutical sector, is actively enhancing its talent pool through strategic stock incentive grants, as detailed in a recent press release. On March 14, 2025, Aligos announced that its Compensation Committee had granted non-qualified stock options to a newly hired employee, allowing them to purchase an aggregate of 4,000 shares of the company?s stock. This grant, effective March 11, 2025, underscores the company s commitment to attracting top talent in the highly competitive biopharmaceutical industry.This latest announcement follows a series of inducement grants that have been pivotal in Aligos s ongoing efforts to secure skilled professionals as they navigate the complex landscape of liver and viral disease therapeutics. Notably, on December 13, 2024, the company granted a non-qualified stock option to purchase 5,500 shares to another new employee, further illustrating the commitment to incentivizing talent growth. Additionally, on October 11, 2024, a significant grant was made that totaled 95,000 shares, with a notable allocation of 75,000 shares specifically awarded to Dr. Hardean Achneck as he transitioned into his role as Chief Medical Officer.
|
|
December 13, 2024
SOUTH SAN FRANCISCO, Calif. In a clear sign of its ongoing strategic growth and commitment to attracting top talent, Aligos Therapeutics, Inc. (Nasdaq: ALGS) recently announced the grant of a non-qualified stock option to a newly hired employee. This latest inducement grant, amounting to 5,500 shares, was approved by the Compensation Committee of the Company?s Board of Directors on December 10, 2024, as part of its efforts to ensure a competitive employment package amidst a thriving biopharmaceutical landscape.The current inducement grant follows an earlier announcement made on October 11, 2024, when the company disclosed the issuance of non-qualified stock options to purchase a total of 95,000 shares to several newly hired employees, including a notable grant of 75,000 shares to Dr. Hardean Achneck, who recently joined as the Chief Medical Officer. This pattern of robust stock option grants signifies Aligos Therapeutics determination to align employee interests with the company s performance as it continues to work toward innovative solutions for liver and viral diseases.
|
|
October 11, 2024
Aligos Therapeutics Expands Talent Pool with Strategic Stock Options Amid MASH Treatment Innovations By , Contributor SOUTH SAN FRANCISCO, Calif. Oct. 11, 2024 In a bold move signaling its commitment to fostering innovation in the biopharmaceutical sector, Aligos Therapeutics, Inc. has announced substantial stock option grants to new employees as part of its strategic growth plan. This initiative, disclosed on October 8, 2024, highlights the company s ongoing dedication to enhancing patient outcomes through cutting-edge therapies for liver diseases and viral infections.The California-based biopharmaceutical company, known for its clinical-stage advancements, granted a total of 95,000 non-qualified stock options as part of its Inducement Grants package to newly appointed employees. A significant portion of this grant was allocated to Dr. Hardean Achneck, who recently joined Aligos as the Chief Medical Officer. Dr. Achneck has been awarded an option to purchase 75,000 shares, underscoring the company s belief in his capabilities to spearhead its medical and clinical strategies as they navigate the complexities of liver disease treatments.
|
|
September 13, 2024
Aligos Therapeutics Rewards New Talent with Stock Inducement Grant: Future Impact on Share Value
SOUTH SAN FRANCISCO, Calif. Sept. 13, 2024 - In a bid to attract and retain top-tier talent, Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced the issuance of a non-qualified stock option as part of an inducement grant to a newly hired employee. This strategic move reflects Aligos? commitment to bolstering its team to advance its clinical-stage biopharmaceutical initiatives.
The Details of the Inducement Grant
Granted by the Compensation Committee of Aligos? Board of Directors, this stock option involves the purchase of an aggregate of 3,500 shares of the company s stock. The grant was made on September 10, 2024, coinciding with the commencement of the new employee s tenure.
Given that the company has a total of approximately 43.5 million shares outstanding, the addition of 3,500 shares via this inducement grant is relatively small. The current share price for Aligos stands at $14.03, making the total value of the grant around $49,105. This strategic move underscores Aligos emphasize on rewarding talent while maintaining shareholder value.
Broader Implications for Aligos Therapeutics
Investor Confidence and Talent Strategy: Aligos Therapeutics focus on cutting-edge treatments for liver and viral diseases necessitates a highly skilled workforce. The recent inducement grant to a new, presumably key employee signals the company s intention to acquire the best talent. This should reassure investors that Aligos is committed to driving its clinical programs forward, potentially leading to significant breakthroughs and gaining competitive advantage in the biopharmaceutical market.
|
|
August 15, 2024
Aligos Therapeutics Announces Reverse Stock Split: What It Means for Investors
In a recent press release, Aligos Therapeutics, a biopharmaceutical company focused on liver and viral diseases, announced a 1-for-25 reverse stock split of its common shares. This move will become effective on August 19, 2024, with the company s stock trading on the Nasdaq Capital Market under the symbol ALGS on a split-adjusted basis.
Prior to the reverse stock split, Aligos had 43.496975 million shares outstanding with a current price of $0.493. Following the split, the total number of shares will be reduced significantly while the price per share will increase proportionally.
The impact of this reverse stock split on Aligos shares is two-fold. On one hand, the reduction in outstanding shares could potentially lead to increased stock value, making individual shares more valuable. On the other hand, some investors may see this move as a red flag, questioning why the company felt the need to execute a reverse stock split.
Overall, the long-term effects of this reverse stock split on Aligos Therapeutics shares remain to be seen. Investors will need to carefully monitor the company s performance and market reactions in the coming months to gauge the true impact of this strategic decision
|
|
